Not checkedNot checked for notices yet.
The role of s100b as a predictor of the functional outcome in geriatric patients with acute cerebrovascular stroke
Walae E. Abdel-Ghaffar, Sekina Ahmed, Ehab Mahmoud El reweny and 3 more
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery · 2019
doi:10.1186/s41983-019-0105-8 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Ischemic stroke is one of the leading causes of disability worldwide [ 1 ]. Though clinical assessment of stroke and evaluation of stroke etiology are always sufficient, reliable biomarkers to support the diagnosis and predict the outcome are not well-established [ 2 ]. Identification of biomarkers that can predict the outcome would be beneficial in stroke management and monitoring the course of stroke therapy. It can also help to direct a specific or personalized therapy to a subgroup of patients most likely to benefit [ 3 ]. Many biomarkers are known to increase during early neurological deterioration (END); or worsening of neurological status from admission to 48–72 h after admission, especially the S100B [ 3 , 4 , 5 ]. Identifying patients at risk of END may be useful for initiating therapies to prevent such worsening. S100B is a calcium-binding protein that was found primarily in glial and Schwann cells. It possesses many of the ideal characteristics of a biochemical marker such as high organ specificity, low molecular size, and a high degree of solubility. S100B acts in bimodal manner. At nanomolar concentrations, S100B stimulates neurite outgrowth in cerebral cortex neurons in vitro and enhances survival of neurons in various systems during development [ 6 ]. SB100 has also a neurotrophic activity during the neuronal maturation and glial cell proliferation [ 7 ]. S100B decreases cell death and protects against mitochondrial function loss resulting from glucose deprivation [ 6 , 8 ]. With its neurotrophic and gliotrophic actions, S100B plays an important role in normal CNS development and recovery after injury.
Abstract licence: CC BY-NC-ND
References28
28 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.